Virtual reality game to reduce pain and anxiety during dupilumab injections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This within-subject randomized crossover study enrolls children aged 6–17 receiving subcutaneous dupilumab for moderate to severe atopic dermatitis and compares an immersive VR game to standard care during injections. Participants are randomized to receive VR during the first injection and standard care during the second, or vice versa, with passive distraction tools allowed and documented in the standard care visits. Pain and anxiety are measured with validated scales around the injection and adverse events are recorded to compare side-effect rates between conditions. Sessions take place at CHU Sainte-Justine in Montreal and children with cognitive impairment, epilepsy, or unable to sit upright are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. between the ages of 6 to 17 years old,
2. suffering from moderate to severe atopic dermatitis and receiving or about to start subcutaneous injections of dupilumab,
3. in the presence of a consenting parent who can understand, read, and write either French or English.

Exclusion Criteria:

1. have a diagnosed cognitive impairment precluding them from playing a virtual reality game,
2. suffer from epilepsy considering the nature of the intervention,
3. cannot be in a sitting position during the procedure as the virtual reality game requires an angle of at least 30 degrees for head-tracking.

Where it's running

• St. Justine's Hospital
  Montreal, Quebec, Canada Recruiting
• CHU Sainte-Justine
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Sylvie Le May, PhD — St. Justine's Hospital
• Study coordinator: Sylvie Le May, PhD
• Email: sylvie.lemay@umontreal.ca
• Phone: 5143454931

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if IBI3027 works as well as Dupilumab for moderate to severe atopic dermatitis

  This study tests whether IBI3027 can help people with moderate to severe atopic dermatitis as effectively as Dupilumab injections.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Guangzhou, Guangdong · NCT07754786

• Dupilumab's effect on anxiety and depression in moderate-to-severe atopic dermatitis

  This project will see if dupilumab reduces anxiety and depression in people with moderate-to-severe atopic dermatitis who are starting or recently started the medicine.

  Recruiting at 4 sites Sanofi · Doha and 6 other locations · NCT07467564

• Single-session intervention to change ambiguity aversion

  This trial tests whether one brief intervention can change how adults with intolerance of uncertainty and anxiety make ambiguous decisions and how their brains respond.

  Recruiting Northwestern University · Chicago, Illinois · NCT06962527

• Observing how adolescents with severe atopic dermatitis respond to dupilumab treatment

  This study looks at how well dupilumab treatment works for teenagers aged 12 to 17 with severe eczema over a year, focusing on their symptoms and quality of life.

  Recruiting at 9 sites Sanofi · Bologna and 8 other locations · NCT06192563

• Examining how dupilumab affects immune cells in atopic dermatitis

  This study is testing how the medication dupilumab affects immune cells in the skin of people with moderate to severe atopic dermatitis.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT05858619

• Using Dupixent and UVB therapy for treating atopic dermatitis

  This study is testing if combining a medication called Dupixent with UVB light therapy can help people with moderate to severe eczema feel better.

  Recruiting Phase 4 Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey · NCT05285839

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.